Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01351519 · ClinicalTrials.gov registry record · Phase 2
A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors
A Phase 2 study, sponsored by MultiCare Health System Research Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT01351519: Clinical Trial Phase 2 study, sponsored by MultiCare Health System Research Institute.
NCT01351519 is a Phase 2 study that was terminated before completion, run by MultiCare Health System Research Institute. The registered enrollment target is 16 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01351519, a Phase 2 study, was terminated before completion, sponsored by MultiCare Health System Research Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
In this study subjects will be administered a single oral dose of Aminolevulinic Acid (ALA) prior to surgical resection of their brain tumor. The ALA ultimately causes brain tumor tissue to fluoresce or light up under ultraviolet light. During surgery an ultraviolet light in the microscope chain will be turned on. The tumor tissue will fluoresce bright pink allowing the surgeon to more easily differentiate tumor tissue from normal brain tissue. The aim of the study is to determine whether ALA and fluorescent visualization of tumor tissue improves the surgeon's ability to completely resect or remove the brain tumor.
Primary Outcome
Determine time-to-progression compared to that in comparable cases performed without the aid of ALA.
Interventions
- DRUG Aminolevulinic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2011-05 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
Why NCT01351519 stopped before completion
NCT01351519 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which Aminolevulinic Acid is the first listed.
NCT01351519 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01351519 about?
NCT01351519 is a clinical study titled "A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors". In this study subjects will be administered a single oral dose of Aminolevulinic Acid (ALA) prior to surgical resection of their brain tumor. The ALA ultimately causes brain tumor tissue to fluoresce or light up under ultraviolet light. During surgery an ultraviolet light in the microscope chain wil...
What is the current status of trial NCT01351519?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2011-05. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01351519?
The interventions under investigation include: Aminolevulinic Acid (DRUG).
Who is sponsoring clinical trial NCT01351519?
This trial is sponsored by MultiCare Health System Research Institute, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01351519's enrollment target sits among peer trials
16 1908th of 2000 higher than 82 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia